Post-stroke spasticity and motor function · Follow-up analysis · 2025
Does a double dose of shockwave change calf muscles more after a stroke?
This analysis compared a double dose of focused shockwave (two calf muscles) with the standard dose (one calf muscle) after a stroke. Over 24 weeks, ultrasound showed similar muscle fibre length and angle in both groups. One ultrasound measure of muscle stiffness changed differently between them.
- adults with ankle stiffness after a stroke
- 39
- sessions over 2 weeks
- 4
- weeks of follow-up
- 24
Good to know: A closer look at ultrasound results from an earlier trial of 39 people; both groups had shockwave and usual rehab.
Yang SM, Lin HH, Chen YH, et al. Journal of Neuroengineering and Rehabilitation, 2025 · Read the paper ↗
Conceptual animation: a focused front converges, then spreads. Not to scale. Tap the field to send a pulse.
The treatment
Double dose
Focused, twice a week for 2 weeks
- Sessions
- 4, two a week
- Pulses
- 4,000 per session · 2,000 each to the two main calf muscles, aimed with ultrasound
- Strength
- 0.10–0.134mJ/mm² · 4 per second
- Numbing
- None
- Device
- Not named in the paper
- Everyone also got
- Usual rehabilitation
Standard dose
Focused, twice a week for 2 weeks
- Sessions
- 4, two a week
- Pulses
- 2,000 per session · all to the main calf muscle, aimed with ultrasound
- Strength
- 0.10–0.134mJ/mm² · 4 per second
- Numbing
- None
- Device
- Not named in the paper
- Everyone also got
- Usual rehabilitation
Compared with: A standard dose of the same treatment: half the pulses, to the main calf muscle only
Settings are what each study used, not a prescription.
Who took part
39 adults with stiff ankle muscles after a stroke on one side of the body (19 double dose, 20 standard dose).
Side effects
Side effects were not reported in this analysis. Paracetamol was allowed after treatment.
All the numbers and the full appraisal
Every reported result
The results, in numbers.
Adults after unilateral stroke with ankle plantar-flexor spasticity above MAS grade 1. Baseline table lists n=19 double-dose and n=20 control; follow-up denominators varied with about 15% attrition at weeks 12 and 24.
Baseline table lists n=19; source says roughly 15% loss at weeks 12 and 24 and available-case analysis, so later outcome denominators vary and are not reconstructed.
Baseline table lists n=20; source says roughly 15% loss at weeks 12 and 24 and available-case analysis, so later outcome denominators vary and are not reconstructed.
Ultrasound strain elastography1 reported outcome
Strain elastography
Ultrasound strain elastography Source-reported elastography measure; unit not stated in table
Change over time differed between dose groups
GEE group × time interaction
The group-by-time interaction was statistically significant. The accessible table does not provide a between-group effect estimate or confidence interval, so magnitude and clinical importance remain unquantified.
Analysis details and source
Main effects: group p=.222; time p=.209. Avoid interpreting the interaction as proof that double dose is better without the trajectory estimates.
Ultrasonographic muscle measure10 reported outcomes
Pennation angle
Ultrasonographic muscle measure degrees
| Group | n | Baseline | Follow-up |
|---|---|---|---|
| Double-dose focused ESWT | 19 | — | 15.58 (SD 4.78) |
| Control-dose focused ESWT | 20 | — | 16.91 (SD 4.15) |
Values are group summaries identified in the caption; SD denotes standard deviation. CI is a confidence interval; IQR denotes the reported quartiles. A dash means no value was extracted for that cell.
One Friedman test within each group across all five visits (baseline to week 24 after treatment); not a between-group comparison
Within-group Friedman tests; GEE group/time analysis reported separately
Means (SD) are shown for both groups at this visit. The within-group Friedman tests were nonsignificant (double-dose p=0.458, control p=0.861). GEE group, time and group-by-time p values were 0.585, 0.956, 0.569.
Analysis details and source
Table 2 values are means (SD); no change scores were calculated. Table 3 GEE terms are reported as group, time and group×time.
Pennation angle
Ultrasonographic muscle measure degrees
| Group | n | Baseline | Follow-up |
|---|---|---|---|
| Double-dose focused ESWT | 19 | — | 16.13 (SD 3.81) |
| Control-dose focused ESWT | 20 | — | 15.87 (SD 2.88) |
Values are group summaries identified in the caption; SD denotes standard deviation. CI is a confidence interval; IQR denotes the reported quartiles. A dash means no value was extracted for that cell.
One Friedman test within each group across all five visits (baseline to week 24 after treatment); not a between-group comparison
Within-group Friedman tests; GEE group/time analysis reported separately
Means (SD) are shown for both groups at this visit. The within-group Friedman tests were nonsignificant (double-dose p=0.458, control p=0.861). GEE group, time and group-by-time p values were 0.585, 0.956, 0.569.
Analysis details and source
Table 2 values are means (SD); no change scores were calculated. Table 3 GEE terms are reported as group, time and group×time.
Pennation angle
Ultrasonographic muscle measure degrees
| Group | n | Baseline | Follow-up |
|---|---|---|---|
| Double-dose focused ESWT | 19 | — | 16.12 (SD 3.83) |
| Control-dose focused ESWT | 20 | — | 16.59 (SD 2.6) |
Values are group summaries identified in the caption; SD denotes standard deviation. CI is a confidence interval; IQR denotes the reported quartiles. A dash means no value was extracted for that cell.
One Friedman test within each group across all five visits (baseline to week 24 after treatment); not a between-group comparison
Within-group Friedman tests; GEE group/time analysis reported separately
Means (SD) are shown for both groups at this visit. The within-group Friedman tests were nonsignificant (double-dose p=0.458, control p=0.861). GEE group, time and group-by-time p values were 0.585, 0.956, 0.569.
Analysis details and source
Table 2 values are means (SD); no change scores were calculated. Table 3 GEE terms are reported as group, time and group×time.
Pennation angle
Ultrasonographic muscle measure degrees
| Group | n | Baseline | Follow-up |
|---|---|---|---|
| Double-dose focused ESWT | — | — | 16.46 (SD 4.31) |
| Control-dose focused ESWT | — | — | 15.91 (SD 3.43) |
Values are group summaries identified in the caption; SD denotes standard deviation. CI is a confidence interval; IQR denotes the reported quartiles. A dash means no value was extracted for that cell.
One Friedman test within each group across all five visits (baseline to week 24 after treatment); not a between-group comparison
Within-group Friedman tests; GEE group/time analysis reported separately
Means (SD) are shown for both groups at this visit. The within-group Friedman tests were nonsignificant (double-dose p=0.458, control p=0.861). GEE group, time and group-by-time p values were 0.585, 0.956, 0.569.
Analysis details and source
Table 2 values are means (SD); no change scores were calculated. Table 3 GEE terms are reported as group, time and group×time. Table 2 prints no per-visit n: the authors report about 15% loss to follow-up in each group at weeks 12 and 24 and used available-case analysis without imputation, so fewer than the 19 and 20 participants contributed to these means. The exact numbers are not reported, so n is left blank.
Pennation angle
Ultrasonographic muscle measure degrees
| Group | n | Baseline | Follow-up |
|---|---|---|---|
| Double-dose focused ESWT | — | — | 15.02 (SD 3.89) |
| Control-dose focused ESWT | — | — | 16.99 (SD 1.95) |
Values are group summaries identified in the caption; SD denotes standard deviation. CI is a confidence interval; IQR denotes the reported quartiles. A dash means no value was extracted for that cell.
One Friedman test within each group across all five visits (baseline to week 24 after treatment); not a between-group comparison
Within-group Friedman tests; GEE group/time analysis reported separately
Means (SD) are shown for both groups at this visit. The within-group Friedman tests were nonsignificant (double-dose p=0.458, control p=0.861). GEE group, time and group-by-time p values were 0.585, 0.956, 0.569.
Analysis details and source
Table 2 values are means (SD); no change scores were calculated. Table 3 GEE terms are reported as group, time and group×time. Table 2 prints no per-visit n: the authors report about 15% loss to follow-up in each group at weeks 12 and 24 and used available-case analysis without imputation, so fewer than the 19 and 20 participants contributed to these means. The exact numbers are not reported, so n is left blank. Source contradiction: the Results text says the double-dose mean PA "increased slightly from 15.58 degrees (SD = 4.78) at baseline to 15.02 degrees (SD = 3.89) at week 24"; the printed means show a slight decrease. The Table 2 values are kept as printed.
Muscle fascicle length
Ultrasonographic muscle measure cm
| Group | n | Baseline | Follow-up |
|---|---|---|---|
| Double-dose focused ESWT | 19 | — | 4.56 (SD 0.53) |
| Control-dose focused ESWT | 20 | — | 4.3 (SD 0.45) |
Values are group summaries identified in the caption; SD denotes standard deviation. CI is a confidence interval; IQR denotes the reported quartiles. A dash means no value was extracted for that cell.
One Friedman test within each group across all five visits (baseline to week 24 after treatment); not a between-group comparison
Within-group Friedman tests; GEE group/time analysis reported separately
Means (SD) are shown for both groups at this visit. The within-group Friedman tests were nonsignificant (double-dose p=0.938, control p=0.177). GEE group, time and group-by-time p values were 0.340, 0.007, 0.772.
Analysis details and source
Table 2 values are means (SD); no change scores were calculated. Table 3 GEE terms are reported as group, time and group×time.
Muscle fascicle length
Ultrasonographic muscle measure cm
| Group | n | Baseline | Follow-up |
|---|---|---|---|
| Double-dose focused ESWT | 19 | — | 4.83 (SD 0.69) |
| Control-dose focused ESWT | 20 | — | 4.57 (SD 0.59) |
Values are group summaries identified in the caption; SD denotes standard deviation. CI is a confidence interval; IQR denotes the reported quartiles. A dash means no value was extracted for that cell.
One Friedman test within each group across all five visits (baseline to week 24 after treatment); not a between-group comparison
Within-group Friedman tests; GEE group/time analysis reported separately
Means (SD) are shown for both groups at this visit. The within-group Friedman tests were nonsignificant (double-dose p=0.938, control p=0.177). GEE group, time and group-by-time p values were 0.340, 0.007, 0.772.
Analysis details and source
Table 2 values are means (SD); no change scores were calculated. Table 3 GEE terms are reported as group, time and group×time.
Muscle fascicle length
Ultrasonographic muscle measure cm
| Group | n | Baseline | Follow-up |
|---|---|---|---|
| Double-dose focused ESWT | 19 | — | 4.32 (SD 0.81) |
| Control-dose focused ESWT | 20 | — | 4.5 (SD 0.76) |
Values are group summaries identified in the caption; SD denotes standard deviation. CI is a confidence interval; IQR denotes the reported quartiles. A dash means no value was extracted for that cell.
One Friedman test within each group across all five visits (baseline to week 24 after treatment); not a between-group comparison
Within-group Friedman tests; GEE group/time analysis reported separately
Means (SD) are shown for both groups at this visit. The within-group Friedman tests were nonsignificant (double-dose p=0.938, control p=0.177). GEE group, time and group-by-time p values were 0.340, 0.007, 0.772.
Analysis details and source
Table 2 values are means (SD); no change scores were calculated. Table 3 GEE terms are reported as group, time and group×time.
Muscle fascicle length
Ultrasonographic muscle measure cm
| Group | n | Baseline | Follow-up |
|---|---|---|---|
| Double-dose focused ESWT | — | — | 4.68 (SD 0.62) |
| Control-dose focused ESWT | — | — | 4.56 (SD 0.77) |
Values are group summaries identified in the caption; SD denotes standard deviation. CI is a confidence interval; IQR denotes the reported quartiles. A dash means no value was extracted for that cell.
One Friedman test within each group across all five visits (baseline to week 24 after treatment); not a between-group comparison
Within-group Friedman tests; GEE group/time analysis reported separately
Means (SD) are shown for both groups at this visit. The within-group Friedman tests were nonsignificant (double-dose p=0.938, control p=0.177). GEE group, time and group-by-time p values were 0.340, 0.007, 0.772.
Analysis details and source
Table 2 values are means (SD); no change scores were calculated. Table 3 GEE terms are reported as group, time and group×time. Table 2 prints no per-visit n: the authors report about 15% loss to follow-up in each group at weeks 12 and 24 and used available-case analysis without imputation, so fewer than the 19 and 20 participants contributed to these means. The exact numbers are not reported, so n is left blank.
Muscle fascicle length
Ultrasonographic muscle measure cm
| Group | n | Baseline | Follow-up |
|---|---|---|---|
| Double-dose focused ESWT | — | — | 4.27 (SD 0.36) |
| Control-dose focused ESWT | — | — | 4.23 (SD 0.54) |
Values are group summaries identified in the caption; SD denotes standard deviation. CI is a confidence interval; IQR denotes the reported quartiles. A dash means no value was extracted for that cell.
One Friedman test within each group across all five visits (baseline to week 24 after treatment); not a between-group comparison
Within-group Friedman tests; GEE group/time analysis reported separately
Means (SD) are shown for both groups at this visit. The within-group Friedman tests were nonsignificant (double-dose p=0.938, control p=0.177). GEE group, time and group-by-time p values were 0.340, 0.007, 0.772.
Analysis details and source
Table 2 values are means (SD); no change scores were calculated. Table 3 GEE terms are reported as group, time and group×time. Table 2 prints no per-visit n: the authors report about 15% loss to follow-up in each group at weeks 12 and 24 and used available-case analysis without imputation, so fewer than the 19 and 20 participants contributed to these means. The exact numbers are not reported, so n is left blank.
Exploratory post hoc association30 reported outcomes
Elastography and MAS correlation (double-dose)
Exploratory post hoc association Pearson correlation coefficient r
Elastography vs MAS; double-dose ESWT group
Exploratory post hoc correlation: Pearson r=-0.017, p=0.870. This is an association, not a causal or treatment effect.
Analysis details and source
Table 4 reports the complete correlation matrix; no multiplicity-adjusted inference is stated in the source.
Pennation angle and MAS correlation (double-dose)
Exploratory post hoc association Pearson correlation coefficient r
Pennation angle vs MAS; double-dose ESWT group
Exploratory post hoc correlation: Pearson r=0.232, p=0.032. This is an association, not a causal or treatment effect.
Analysis details and source
Table 4 reports the complete correlation matrix; no multiplicity-adjusted inference is stated in the source.
Muscle fascicle length and MAS correlation (double-dose)
Exploratory post hoc association Pearson correlation coefficient r
Muscle fascicle length vs MAS; double-dose ESWT group
Exploratory post hoc correlation: Pearson r=-0.21, p=0.156. This is an association, not a causal or treatment effect.
Analysis details and source
Table 4 reports the complete correlation matrix; no multiplicity-adjusted inference is stated in the source.
Elastography and MAS correlation (control)
Exploratory post hoc association Pearson correlation coefficient r
Elastography vs MAS; control ESWT group
Exploratory post hoc correlation: Pearson r=-0.073, p=0.488. This is an association, not a causal or treatment effect.
Analysis details and source
Table 4 reports the complete correlation matrix; no multiplicity-adjusted inference is stated in the source.
Pennation angle and MAS correlation (control)
Exploratory post hoc association Pearson correlation coefficient r
Pennation angle vs MAS; control ESWT group
Exploratory post hoc correlation: Pearson r=0.003, p=0.982. This is an association, not a causal or treatment effect.
Analysis details and source
Table 4 reports the complete correlation matrix; no multiplicity-adjusted inference is stated in the source.
Muscle fascicle length and MAS correlation (control)
Exploratory post hoc association Pearson correlation coefficient r
Muscle fascicle length vs MAS; control ESWT group
Exploratory post hoc correlation: Pearson r=-0.207, p=0.145. This is an association, not a causal or treatment effect.
Analysis details and source
Table 4 reports the complete correlation matrix; no multiplicity-adjusted inference is stated in the source.
Elastography and MTS correlation (double-dose)
Exploratory post hoc association Pearson correlation coefficient r
Elastography vs MTS; double-dose ESWT group
Exploratory post hoc correlation: Pearson r=0.185, p=0.072. This is an association, not a causal or treatment effect.
Analysis details and source
Table 4 reports the complete correlation matrix; no multiplicity-adjusted inference is stated in the source.
Pennation angle and MTS correlation (double-dose)
Exploratory post hoc association Pearson correlation coefficient r
Pennation angle vs MTS; double-dose ESWT group
Exploratory post hoc correlation: Pearson r=-0.08, p=0.469. This is an association, not a causal or treatment effect.
Analysis details and source
Table 4 reports the complete correlation matrix; no multiplicity-adjusted inference is stated in the source.
Muscle fascicle length and MTS correlation (double-dose)
Exploratory post hoc association Pearson correlation coefficient r
Muscle fascicle length vs MTS; double-dose ESWT group
Exploratory post hoc correlation: Pearson r=0.3, p=0.040. This is an association, not a causal or treatment effect.
Analysis details and source
Table 4 reports the complete correlation matrix; no multiplicity-adjusted inference is stated in the source.
Elastography and MTS correlation (control)
Exploratory post hoc association Pearson correlation coefficient r
Elastography vs MTS; control ESWT group
Exploratory post hoc correlation: Pearson r=-0.125, p=0.234. This is an association, not a causal or treatment effect.
Analysis details and source
Table 4 reports the complete correlation matrix; no multiplicity-adjusted inference is stated in the source.
Pennation angle and MTS correlation (control)
Exploratory post hoc association Pearson correlation coefficient r
Pennation angle vs MTS; control ESWT group
Exploratory post hoc correlation: Pearson r=-0.01, p=0.931. This is an association, not a causal or treatment effect.
Analysis details and source
Table 4 reports the complete correlation matrix; no multiplicity-adjusted inference is stated in the source.
Muscle fascicle length and MTS correlation (control)
Exploratory post hoc association Pearson correlation coefficient r
Muscle fascicle length vs MTS; control ESWT group
Exploratory post hoc correlation: Pearson r=-0.123, p=0.392. This is an association, not a causal or treatment effect.
Analysis details and source
Table 4 reports the complete correlation matrix; no multiplicity-adjusted inference is stated in the source.
Elastography and PROM correlation (double-dose)
Exploratory post hoc association Pearson correlation coefficient r
Elastography vs PROM; double-dose ESWT group
Exploratory post hoc correlation: Pearson r=0.164, p=0.111. This is an association, not a causal or treatment effect.
Analysis details and source
Table 4 reports the complete correlation matrix; no multiplicity-adjusted inference is stated in the source.
Pennation angle and PROM correlation (double-dose)
Exploratory post hoc association Pearson correlation coefficient r
Pennation angle vs PROM; double-dose ESWT group
Exploratory post hoc correlation: Pearson r=-0.129, p=0.240. This is an association, not a causal or treatment effect.
Analysis details and source
Table 4 reports the complete correlation matrix; no multiplicity-adjusted inference is stated in the source.
Muscle fascicle length and PROM correlation (double-dose)
Exploratory post hoc association Pearson correlation coefficient r
Muscle fascicle length vs PROM; double-dose ESWT group
Exploratory post hoc correlation: Pearson r=0.423, p=0.003. This is an association, not a causal or treatment effect.
Analysis details and source
Table 4 reports the complete correlation matrix; no multiplicity-adjusted inference is stated in the source.
Elastography and PROM correlation (control)
Exploratory post hoc association Pearson correlation coefficient r
Elastography vs PROM; control ESWT group
Exploratory post hoc correlation: Pearson r=-0.094, p=0.374. This is an association, not a causal or treatment effect.
Analysis details and source
Table 4 reports the complete correlation matrix; no multiplicity-adjusted inference is stated in the source.
Pennation angle and PROM correlation (control)
Exploratory post hoc association Pearson correlation coefficient r
Pennation angle vs PROM; control ESWT group
Exploratory post hoc correlation: Pearson r=0.045, p=0.704. This is an association, not a causal or treatment effect.
Analysis details and source
Table 4 reports the complete correlation matrix; no multiplicity-adjusted inference is stated in the source.
Muscle fascicle length and PROM correlation (control)
Exploratory post hoc association Pearson correlation coefficient r
Muscle fascicle length vs PROM; control ESWT group
Exploratory post hoc correlation: Pearson r=0.063, p=0.663. This is an association, not a causal or treatment effect.
Analysis details and source
Table 4 reports the complete correlation matrix; no multiplicity-adjusted inference is stated in the source.
Elastography and Timed Up and Go test correlation (double-dose)
Exploratory post hoc association Pearson correlation coefficient r
Elastography vs Timed Up and Go test; double-dose ESWT group
Exploratory post hoc correlation: Pearson r=-0.149, p=0.148. This is an association, not a causal or treatment effect.
Analysis details and source
Table 4 reports the complete correlation matrix; no multiplicity-adjusted inference is stated in the source.
Pennation angle and Timed Up and Go test correlation (double-dose)
Exploratory post hoc association Pearson correlation coefficient r
Pennation angle vs Timed Up and Go test; double-dose ESWT group
Exploratory post hoc correlation: Pearson r=0.077, p=0.481. This is an association, not a causal or treatment effect.
Analysis details and source
Table 4 reports the complete correlation matrix; no multiplicity-adjusted inference is stated in the source.
Muscle fascicle length and Timed Up and Go test correlation (double-dose)
Exploratory post hoc association Pearson correlation coefficient r
Muscle fascicle length vs Timed Up and Go test; double-dose ESWT group
Exploratory post hoc correlation: Pearson r=-0.644, p=<0.001. This is an association, not a causal or treatment effect.
Analysis details and source
Table 4 reports the complete correlation matrix; no multiplicity-adjusted inference is stated in the source.
Elastography and Timed Up and Go test correlation (control)
Exploratory post hoc association Pearson correlation coefficient r
Elastography vs Timed Up and Go test; control ESWT group
Exploratory post hoc correlation: Pearson r=-0.004, p=0.056. This is an association, not a causal or treatment effect.
Analysis details and source
Table 4 reports the complete correlation matrix; no multiplicity-adjusted inference is stated in the source. Source contradiction: with 20 control participants assessed at up to five visits, a Pearson r of −0.004 corresponds to p of about 0.97–0.99, not the printed 0.056; one of the two printed values is probably a typo. Both are kept as printed.
Pennation angle and Timed Up and Go test correlation (control)
Exploratory post hoc association Pearson correlation coefficient r
Pennation angle vs Timed Up and Go test; control ESWT group
Exploratory post hoc correlation: Pearson r=-0.105, p=0.374. This is an association, not a causal or treatment effect.
Analysis details and source
Table 4 reports the complete correlation matrix; no multiplicity-adjusted inference is stated in the source.
Muscle fascicle length and Timed Up and Go test correlation (control)
Exploratory post hoc association Pearson correlation coefficient r
Muscle fascicle length vs Timed Up and Go test; control ESWT group
Exploratory post hoc correlation: Pearson r=-0.245, p=0.084. This is an association, not a causal or treatment effect.
Analysis details and source
Table 4 reports the complete correlation matrix; no multiplicity-adjusted inference is stated in the source.
Elastography and Barthel index correlation (double-dose)
Exploratory post hoc association Pearson correlation coefficient r
Elastography vs Barthel index; double-dose ESWT group
Exploratory post hoc correlation: Pearson r=0.017, p=0.870. This is an association, not a causal or treatment effect.
Analysis details and source
Table 4 reports the complete correlation matrix; no multiplicity-adjusted inference is stated in the source.
Pennation angle and Barthel index correlation (double-dose)
Exploratory post hoc association Pearson correlation coefficient r
Pennation angle vs Barthel index; double-dose ESWT group
Exploratory post hoc correlation: Pearson r=-0.006, p=0.956. This is an association, not a causal or treatment effect.
Analysis details and source
Table 4 reports the complete correlation matrix; no multiplicity-adjusted inference is stated in the source.
Muscle fascicle length and Barthel index correlation (double-dose)
Exploratory post hoc association Pearson correlation coefficient r
Muscle fascicle length vs Barthel index; double-dose ESWT group
Exploratory post hoc correlation: Pearson r=0.063, p=0.683. This is an association, not a causal or treatment effect.
Analysis details and source
Table 4 reports the complete correlation matrix; no multiplicity-adjusted inference is stated in the source.
Elastography and Barthel index correlation (control)
Exploratory post hoc association Pearson correlation coefficient r
Elastography vs Barthel index; control ESWT group
Exploratory post hoc correlation: Pearson r=0.124, p=0.237. This is an association, not a causal or treatment effect.
Analysis details and source
Table 4 reports the complete correlation matrix; no multiplicity-adjusted inference is stated in the source.
Pennation angle and Barthel index correlation (control)
Exploratory post hoc association Pearson correlation coefficient r
Pennation angle vs Barthel index; control ESWT group
Exploratory post hoc correlation: Pearson r=0.171, p=0.144. This is an association, not a causal or treatment effect.
Analysis details and source
Table 4 reports the complete correlation matrix; no multiplicity-adjusted inference is stated in the source.
Muscle fascicle length and Barthel index correlation (control)
Exploratory post hoc association Pearson correlation coefficient r
Muscle fascicle length vs Barthel index; control ESWT group
Exploratory post hoc correlation: Pearson r=0.296, p=0.053. This is an association, not a causal or treatment effect.
Analysis details and source
Table 4 reports the complete correlation matrix; no multiplicity-adjusted inference is stated in the source.
How treatment was delivered
4 Hz; EFD 0.10–0.134 mJ/mm²; four sessions, twice weekly for two weeks; ultrasound-guided targeting; no local anesthetic.
Double-dose: 4,000 pulses/session (2,000 gastrocnemius, 2,000 soleus). Control: 2,000 pulses/session to gastrocnemius only. Both groups continued usual rehabilitation.
Adverse-event counts were not reported in the analyzed article. Paracetamol was permitted after treatment and NSAIDs discouraged.
Secondary analysis of an existing trial; the analysis is exploratory for ultrasound architecture. Available-case analysis without imputation and approximately 15% attrition at later assessments may bias results.
Table 1 reports baseline n=19 and n=20, while some percentages imply different denominators. This internal denominator inconsistency and changing follow-up counts require caution; no missing denominators were reconstructed.
Ultrasound was assessed by one assessor; no healthy comparison group or neurophysiological assessment was included. Supplementary material was not available.
Findings checked against the full source by a separate automated reviewer.
Limitations noted by the reviewers
- Secondary analysis of an existing trial; the analysis is exploratory for ultrasound architecture. Available-case analysis without imputation and approximately 15% attrition at later assessments may bias results.
- Table 1 reports baseline n=19 and n=20, while some percentages imply different denominators. This internal denominator inconsistency and changing follow-up counts require caution; no missing denominators were reconstructed.
- Ultrasound was assessed by one assessor; no healthy comparison group or neurophysiological assessment was included. Supplementary material was not available.
Source-linked critical reading
Post hoc analysis of a randomized trial
Technical source record
Full-text XML and all four table-wraps (baseline characteristics, within-group measures, GEE tests and correlations) read directly; figure caption, discussion, limitations and end-matter read; supplements unavailable.
This secondary analysis found no clear dose-group difference in muscle fascicle length or pennation angle. A stiffness measure changed differently over time, but the study does not establish that a higher dose improves function.
In adults with post-stroke ankle plantar-flexor spasticity, do double-dose versus standard-dose focused ESWT regimens produce different ultrasound muscle-architecture outcomes over 24 weeks, and are these measures associated with clinical outcomes?
Secondary analysis of a previously published randomized dose-comparison trial. Ultrasound outcomes were assessed at baseline and 1, 4, 12 and 24 weeks after treatment; clinical associations were exploratory.
Adults with unilateral stroke and plantar-flexor spasticity above MAS grade 1. Baseline table lists 19 participants in the double-dose group and 20 in control; approximately 15% were lost at week 12 and week 24.
Focused ESWT, 4 Hz, EFD 0.10–0.134 mJ/mm², four sessions over two weeks. Double-dose: 4,000 pulses/session, 2,000 each to gastrocnemius and soleus. Control: 2,000 pulses/session to gastrocnemius. Ultrasound guided targeting; no local anesthetic. Usual rehabilitation continued.
The control was an active ESWT dose, not sham or no treatment. Both groups also continued usual rehabilitation and orthoses as applicable.
Primary analysis considered pennation angle (PA), muscle fascicle length (MFL) and strain elastography. No between-group time interaction was found for PA (p=.569) or MFL (p=.772); elastography had a group-by-time interaction (p=.008). MFL had a time effect (p=.007), without a group effect.
The authors conclude there were no significant between-group differences in PA or MFL, while changes in stiffness measured by strain elastography differed between the groups over time. Exploratory correlations in the double-dose arm linked MFL with MTS (r=.300), PROM (r=.423) and TUG (r=−.644); these are associations, not treatment effects or causal mechanisms.
Adverse-event counts are not reported in the article results. Paracetamol was permitted after treatment; NSAIDs were discouraged.
This is a secondary analysis of a small trial with available-case handling and about 15% loss at later follow-ups. No healthy control group was included; ultrasound was assessed by one assessor. The clinical correlation analyses were within-group and exploratory. Supplementary files were cited but not available in the retrieved XML.
The findings concern ultrasound architecture in post-stroke ankle spasticity and compare two active doses. They do not establish dose superiority for patient-important function or generalize to other causes or stages of spasticity.
Larger trials should prespecify ultrasound and patient-important outcomes, retain participants through long-term visits, report uncertainty and missing-data handling, and test dose differences in a design powered for interaction effects.
Read the original article.
Dose-response effectiveness of focused shockwave therapy on ultrasonographic muscular properties in patients with stroke exhibiting ankle spasticity.
Yang SM, Lin HH, Chen YH, Lu YL, Wu CH, Chen WS, Lin MT. · Journal of neuroengineering and rehabilitation · 2025
Open the publication record or available full-text files.
Checked against the full paper · Clinical review: Dr. Marcus Yu Bin Pai, · How we review →